Newsfeeds Archive - Page 21 of 194

2 minute read

News

MediWound Said Partner Vericel Has Received The First Lot Of Nexobrid Finished Product From Mediwound For The U.S. Commercial Market In June 2023

August 2, 8:04 AM

Our Partner, Vericel Corporation Inc. ("Vericel") has received the first lot of NexoBrid® finished product from MediWound Ltd. ("we" or the "Company") for the U.S. commercial market in

MDWD

1 minute read

News
Tech

Nikola Announced An Additional $16.3M Has Been Awarded To Nikola To Support Seven Open-network Hydrogen Refueling Stations

By Charles Gross

August 1, 7:57 AM

Nikola Corporation (NASDAQ:NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, today announced an additional $16.3 million has been

NKLA

1 minute read

Vision Marine Technologies Announced That It Has Entered Into A Definitive Agreement With Investors For The Issuance And Sale Of 493,832 Of Its Common Shares At $4.05/Share, For Gross Proceeds Of ~$2M In A Registered Direct Offering

By Charles Gross

August 1, 7:52 AM

Vision Marine Technologies Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”), a global leader and innovator within the performance electric recreational boating industry, today announced that

VMAR

2 minute read

M&A
News

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction

By Charles Gross

August 1, 7:12 AM

Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc.

EQRX

1 minute read

M&A
News

Charge Enterprises Announces Acquisition of Greenspeed Energy Solutions For Up To $15M

By Charles Gross

August 1, 7:08 AM

Charge Enterprises, Inc. (NASDAQ:CRGE) ("Charge" or the "Company"), an electrical, broadband and electric vehicle ("EV") charging infrastructure company, announced today, the successful

CRGE

1 minute read

OPC Energy Ltd., Subsidiary of Kenon Holdings., Announced Update In Respect Of Bid In Israel Land Authority Tender To Design and Build Electricity Generation Facilities Using Photovoltaic Technology

By Charles Gross

August 1, 6:20 AM

enon Holdings Ltd.'s (NYSE:KEN, TASE: KEN)) ("Kenon") subsidiary OPC Energy Ltd. ("OPC") announced on May 11, 2023 that OPC's subsidiary, OPC Power Plants Ltd.1 (the "Awardee") won a

KEN

1 minute read

China Natural Resources To Sell All Outstanding Shares Of Precise Space-time Technology Limited To Feishang Group Limited For Consideration Of Approximately $13.2M

By Charles Gross

July 31, 4:58 AM

China Natural Resources, Inc. (NASDAQ:CHNR) (the "Company") announced today that it has agreed to sell all outstanding shares of Precise Space-Time Technology Limited ("Precise Space-Time

CHNR

2 minute read

Events
News

4D Molecular Therapeutics On Saturday, Announced Additional Interim Data From Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial In Patients with Wet AMD At ASRS 2023

By Charles Gross

July 30, 9:40 AM

4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced additional

FDMT

1 minute read

News
Tech

AWS Expands Amazon Bedrock With Additional Foundation Models, New Model Provider, and Advanced Capability to Help Customers Build Generative AI Applications Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today at AWS Summi…

By Charles Gross

July 26, 11:27 AM

Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), today at AWS Summit New York announced the expansion of its fully managed foundation model (FM) service Amazon Bedrock to include the addition

AMZN

1 minute read

News

Inozyme Pharma Announced Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency; Said Updated Cash Runway Expected To Fund Cash Flow Requirements Into Q1 2025

By Charles Gross

July 26, 7:52 AM

Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic

INZY